HIGHLIGHTS
- Who: IDWeek, and Maurice, Policar from the , Elmhurst, New York, USA have published the Article: Congress Feature HIV Treatment at Author:, in the Journal: (JOURNAL)
SUMMARY
Some addressed the (off label) use of bimonthly injectable cabotegravir/rilpivirine (CAB/RPV) for patients who were not virally suppressed. Although these agents have proven to be effective, original studies and FDA approval support their use only in people who have achieved viral suppression with oral agents. In Hastie`s cohort, patients with viral loads over 10,000 were also treated with additional agents at the time . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.